NKG2D and its ligands in cancer

Curr Opin Immunol. 2018 Apr:51:55-61. doi: 10.1016/j.coi.2018.02.004. Epub 2018 Mar 9.

Abstract

NKG2D is an activating immune receptor expressed by NK and effector T cells. Induced expression of NKG2D ligand on tumor cell surface during oncogenic insults renders cancer cells susceptible to immune destruction. In advanced human cancers, tumor cells shed NKG2D ligand to produce an immune soluble form as a means of immune evasion. Soluble NKG2D ligands have been associated with poor clinical prognosis in cancer patients. Harnessing NKG2D pathway is considered a viable avenue in cancer immunotherapy over recent years. In this review, we will discuss the progress and perspectives.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Disease Susceptibility / immunology*
  • Humans
  • Immune Evasion
  • Immunotherapy, Adoptive
  • Ligands
  • Lymphocyte Subsets / immunology*
  • Lymphocyte Subsets / metabolism*
  • NK Cell Lectin-Like Receptor Subfamily K / metabolism*
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • Neoplasms / metabolism*
  • Neoplasms / therapy
  • Protein Binding
  • Receptors, Antigen, T-Cell / metabolism
  • Signal Transduction

Substances

  • Ligands
  • NK Cell Lectin-Like Receptor Subfamily K
  • Receptors, Antigen, T-Cell